Must have received first-line multimodal therapy with surgery followed by temozolomide (unless MGMT promoter unmethylated) and radiation (subjects with GBM must have received temozolomide and radiation concurrently)
Patients who received radiation therapy within the last  weeks; radiation exposure may not exceed % of marrow area
STEP I: Patients must have received no more than one cycle ( weeks or less) of prior chemotherapy and no more than  mg of prior dexamethasone (or equivalent dose of prednisone) for treatment of symptomatic myeloma; they should not have been exposed to lenalidomide, bortezomib or carfilzomib for treatment of symptomatic myeloma; prior radiation therapy to symptomatic lesions is allowed provided there are no residual toxicity related to radiation and blood counts that meet the study requirements
Patients with cervix cancer who have received any previous radiation or chemotherapy
Patients who have received prior chemotherapy or radiation therapy are not eligible
Children who have previously received chemotherapy, radiation therapy or any anti-leukemic therapy are not eligible for this protocol, with the exception of cytarabine for the treatment of TMD
Patients who have received any previous chemotherapy or radiation therapy are not eligible
Patients having received palliative radiotherapy for extracranial metastasis(es) are eligible as long as there are  cancerous deposits that have not received prior radiation therapy (RT) and they meet the following criteria\r\n* No prior radiation therapy (>  Gy) to the metastasis intended to be treated with SBRT
Prior radiation therapy is allowed; patients must not have received minimal radiation therapy (=< % of their total marrow volume) within  weeks prior to the initiation of study treatment; otherwise, patients must not have received radiation therapy (> % of their total marrow volume) within  weeks prior to the initiation of study treatment; patients who have received prior radiation to % or more of their total marrow volume will be excluded
Patients may not receive or have received any radiation therapy at the biopsy sites.
Received radiation therapy to the lung >  Gy within  months of first dose of study treatment.
Received other recent antitumor therapy including any standard chemotherapy or radiation within  days (or have not yet recovered from any actual toxicities of the most recent therapy) prior to the first scheduled dose of MM-
Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, and radiotherapy prior to participating in this trial\r\n* No prior myelosuppressive chemotherapy for at least  days prior to study enrollment\r\n* Must not have received craniospinal radiation therapy within  weeks prior to study entry and no involved field radiation therapy for  weeks prior to study enrollment\r\n* If patients received prior monoclonal antibody treatment, at least three half-lives must be elapsed by the time of treatment initiation\r\n* No investigational drugs for  weeks prior to study enrollment\r\n* No prior therapy with mTOR inhibitors (including sirolimus, temsirolimus or everolimus)
Participants who have received radiation therapy within  weeks of starting study drug; Note: participants who have received radiation therapy to a small volume (e.g. stereotactic radiosurgery to the CNS) will be eligible if completed >  week prior to starting study drug
Has received prior radiotherapy within  weeks of start of study therapy or received lung radiation therapy of > Gray (Gy) within  months of the first dose of study therapy
Patients who have received prior radiation or chemotherapy may be enrolled on this study
Received more than one course of radiation therapy or more than a total dose of  Gy.
Patients must not have received any prior chemotherapy, immunotherapy or bone marrow transplant for the treatment of their tumor; prior use of temozolomide during radiation at maximum of the standard pediatric dosing (defined as  mg/m^ /dose continuously during radiation therapy for  days) or dexamethasone is allowed
Received radiation therapy to the lung that is >  Gy within  months of the first dose of study drug.
Patients may not have received prior radiation therapy to a site of recurrence which would require overlap of appreciable radiation dose
Patients who have received prior radiation of osseous lesions
Subjects must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study and meet time restrictions from end of prior therapy as stated below: \r\n* Myelosuppressive chemotherapy: Subjects must have received the last dose of myelosuppressive therapy at least  weeks prior to study registration or at least  weeks if therapy included nitrosourea\r\n* Investigational/biological agent: Subjects must have received the last dose of other investigational or biological agent >  days prior to study registration; subjects must not have received poly-ICLC in the past\r\n* Radiation therapy (XRT): Subjects must be >=  weeks since the completion of radiation therapy\r\n* Study specific limitations on prior therapy: There is no limit on the number of prior treatment regimens or received doses of radiation therapy\r\n* Growth factor(s): Subjects must not have received any hematopoietic growth factors within  days of study entry or  days for pegfilgrastim\r\n* Prior surgery: Subjects must be >=  weeks from prior surgery\r\n* Steroids: Subjects must be on a stable steroid dose for  days prior to study entry if they are on steroid treatment
Patients who have previously received radiation therapy
Patients who received other chemotherapeutics or investigational agents in addition to their radiation therapy and concomitant temozolomide treatment
Patients who have received radiation therapy, radionuclide therapy or undergone surgery within certain duration ( weeks) of enrollment
Subjects must not have received chemotherapy within  weeks of planned first (st) day of radiation therapy (RT)
Patients who have received maximally allowed doses (given in  Gy fractionations, or equivalent) of previous radiation therapy to various organs; patients who previously have received a higher than allowed dose of radiation to a small lung, liver and brain volume, will be evaluated by the radiation oncologist to determine if the patient is eligible for study
Patients can have had any number of prior therapies, however must have had previous therapy with at least radiotherapy; patients with oligodendroglioma must have also received chemotherapy in addition to radiation therapy
STUDY TREATMENT: Patients must have received systemic radiosensitizing chemotherapy with definitive pelvic radiation therapy; patients may have received partial amount of chemotherapy and radiation (both) to be eligible
Prior chemotherapy or radiation therapy is allowed if received >=  weeks before study enrollment
Patients who have received prior radiation or chemotherapy may be enrolled on this study
Patients who have received radiation therapy, major surgery, other locoregional therapy, within  weeks prior to the first date of SBRT
Patients must have received prior radiation therapy and must have an interval of greater than or equal to  weeks ( days) from the completion of radiation therapy to study entry except if there is unequivocal evidence for tumor recurrence (such as histological confirmation or advanced imaging data such as positron emission tomography [PET] scan) in which case the principal investigators discretion may determine appropriate timepoint at which study therapy may begin
Subjects who have not received radiation therapy as part of their prior treatment are excluded
Has received prior systemic cytotoxic chemotherapy, antineoplastic biological therapy (e.g., cetuximab), major surgery within  weeks of the first dose of trial treatment; received thoracic radiation therapy of >  Gy within  months of the first dose of trial treatment
Patients must have received prior radiation therapy and standard temozolomide; patients who have received additional therapies for previous progressions will be considered eligible
BC patients with a previous history of another cancer who have NOT received any chemotherapy or chemotherapy and radiation, but have only received surgical treatments are eligible;
Patients who have been treated with any combination of surgical resection and neoadjuvant/adjuvant conventional chemoradiation therapy for resectable disease or conventional chemoradiation as definitive treatment for unresectable or borderline resectable disease are eligible for the study, provided that at least  days have elapsed since completing any previous radiation treatment; patients who have been receiving continued chemotherapy following their initial radiation treatment are eligible regardless of when the most recent chemotherapy was received; those patients who have received prior radiation therapy will constitute Cohort A and will receive SBRT as  Gy x 
Radiation therapy for treatment of the primary tumor within  weeks of cycle , day ; patients who have received palliative radiation to a single site and recovered are eligible
Patients who have received chemotherapy and/or radiation therapy within  weeks unless there is evidence of rapidly progressive disease; in the event that subjects have received chemotherapy <  weeks from the date of enrollment, they may be included provided they have recovered from the associated non-hematological toxicities to less than or equal to grade ; hydroxyurea is allowed up to  hours prior to starting therapy in the setting of rapidly proliferating disease
Patients must not have received chemotherapy and/or radiation therapy within  weeks of start of protocol treatment; hydroxyurea is allowed up to  hours prior to starting therapy in the setting of rapidly proliferating disease
Patient received radiotherapy within  weeks prior to the first dose of study treatment except localized radiation therapy for symptomatic bone metastasis
Patients who have received prior radiation therapy for HNSCC
Patients must not have received any anti-cancer therapy (cytotoxic chemotherapy, targeted therapy or radiation) within the past  days prior to initiation of study therapy
Patients may have received radiation therapy to painful bone metastases or areas of impending bone fracture as long as radiation therapy is completed >=  weeks prior to day  of cycle  of treatment; patients who have received prior radiotherapy must have recovered from toxicity (=< grade ) induced by this treatment; baseline radiologic scans must be obtained after completion of radiation
Patients must not have received systemic chemotherapy for at least  weeks, and must not have received prior radiation therapy to the tumor site being irradiated on this study
Patients who have received radiation to the spleen within  months prior to registration
Unresectable low-grade gliomas that have received at least two chemotherapy/biologic regimens; radiation therapy counts as a biologic regimen; patients may not have received radiation therapy to the index lesion within  year of enrollment; patients may have tumor spread within the central nervous system (CNS); histologic confirmation of eligibility is required if tissue is available
Patients may not have received radiation to the index lesion within  year of enrollment
Participants who have received prior radiation therapy to anatomical sites other than brain or skeleton
Subjects who have received radiation therapy, major surgery, other locoregional therapy, within  weeks prior to the first dose of study drug
Patients must have received prior external beam radiation therapy to the region proposed for SRS re-irradiation at least  months prior to planned re-irradiation\r\n* For patients who were previously treated at an outside institution, adequate records must be available to determine the true dose the cord/cauda received during prior radiation therapy (RT); sufficiency of the treatment records will be assessed and signed-off by the Medical Physics investigator
Patients must not have received radiation for a minimum of two weeks prior
Patients must not have received radiation therapy within the past  weeks
Patients must have previously received standard initial therapy, including attempted gross total resection, where safely feasible, and in appropriate circumstances (e.g., those older than one year at initial diagnosis, with non- metastatic tumors and at least microscopic residual disease) involved field fractionated radiation therapy (RT); patients may have received re-irradiation but not to the index lesion within  weeks
Either:\r\n* Patients who have received radiation therapy (RT): Previously (>=  months before to enrollment) completed treatment for pancreatic or periampullary adenocarcinoma consisting of either surgical resection with neoadjuvant/adjuvant conventional conformal radiation therapy (CRT) for resectable disease or conventional CRT as definitive treatment for unresectable disease; these patients who have received prior radiation therapy will constitute Cohort A and will receive SBRT as  Gy x ; patients may be receiving continued chemotherapy post initial CRT; OR\r\n* Patients who have not received RT: Previously (>=  months before retreatment) initiated treatment for pancreatic or periampullary adenocarcinoma consisting of chemotherapy alone for unresectable disease or surgical resection with neoadjuvant/adjuvant chemotherapy for resectable disease; these patients who have not received prior radiation therapy will constitute Cohort B and will receive SBRT as . Gy x ; patients must have attempted chemotherapy upon initial diagnosis
Patients must not have received prior radiation therapy to the involved breast at any time for any reason
Patients with cervix cancer who have received any previous radiation or chemotherapy
Patients should be at least four weeks from the last day of therapeutic radiation or cytotoxic chemotherapy or from antibody therapy, or at least five half-lives from non-cytotoxic targeted or biologic therapy; patients may have received palliative radiation immediately before (or during) treatment provided radiation is not to the only target lesion available
Patients must be >=  weeks beyond treatment with a cytotoxic chemotherapy regimen, or therapeutic radiation, or major surgery; patients may have received palliative localized radiation immediately before or during treatment provided that radiation is not delivered to the only site of disease being treated under this protocol; for biologic/targeted agents patients must be >=  half-lives or >=  weeks from the last dose (whichever comes first); patients previously treated with vemurafenib monotherapy do not have to stop medication before they start on the protocol
Tumor types  tumor type/location:\r\n* Stratum A: newly diagnosed diffuse intrinsic pontine gliomas OR any biopsy proven high-grade glioma involving the brainstem; patients may not have received chemotherapy during or after radiation; patients must be registered within - weeks of completing radiation\r\n* Stratum B: newly diagnosed, non-brainstem high-grade glioma; patients may not have received chemotherapy during or after radiation; patients must be registered within - weeks of completing radiation\r\n* Stratum C: unresectable low-grade gliomas that have received at least two chemotherapy/biologic regimens; patients may not have received radiation to the index lesion within  year of enrollment \r\n* Stratum D: non-brainstem high-grade gliomas that have recurred following treatment\r\n* Stratum E: newly diagnosed high-grade gliomas or brain stem gliomas who received chemotherapy during radiation therapy; patients may not have received chemotherapy after radiation therapy was completed; patients must be registered within - weeks of completing radiation  \r\n* Stratum F: newly diagnosed high-grade gliomas with metastatic disease within the central nervous system (CNS) requiring craniospinal radiation therapy; patients may or may not have received chemotherapy during radiation, but cannot have received chemotherapy after radiation therapy was completed; patients must be registered within - weeks of completing radiation
Patients enrolled in Strata A and B may not have received any prior chemotherapy or anti-glioma therapy of any type other than radiation therapy; patients enrolled on Stratum C must have received at least two prior chemotherapy or biologic therapy regimens and may not have received radiation to the index lesion within  year of enrollment; patients on Strata A, B, E, and F cannot have received chemotherapy after radiation therapy was completed
Subjects who received radiation therapy within  weeks of randomization (CD)
Has received re-radiation to recurrent disease (other than standard frontline adjuvant radiation therapy)
Patients who have received prior surgical site radiation
Received more than one course of radiation therapy or more than a total dose of  Gy. May have received radiosurgery as part of initial therapy; however, the dose counts against the total dose limit.
Patients who have received previous radiation therapy to critical organs exceeding any of the limits shown below, are excluded:
Patients who have received previous chemotherapy or radiation therapy (does NOT include steroids)
Prior treatment with any cytotoxic chemotherapy except as an adjuvant therapy; patient should not have received gemcitabine within  months of starting the study treatment; -flourouracil or radiation treatment should be received more than  weeks prior to receiving the study drug
Patients who have received prior pulmonary radiation
Patients that have received prior radiation to the lung, excluding prior mediastinal radiation
Received radiation therapy to the lung that is > Gy within  months of the first dose of study medication.
Prior radiation therapy is allowed; patients must not have received minimal radiation therapy (=< % of their total marrow volume) within  weeks prior to the initiation of study treatment; otherwise, patients must not have received radiation therapy (> % of their total marrow volume) within  weeks prior to the initiation of study treatment; patients who have received prior radiation to % or more of their total marrow volume will be excluded
Patients who have previously received systemic, radiation or other treatment for uterine cancer
Prior Therapy  Patients must have not received any prior therapy other than surgery, radiation and/or steroids.
Received prior systemic cytotoxic chemotherapy, biological therapy, major surgery within  weeks of first dose of study drug; received thoracic radiation therapy of >  gray (Gy) within  months of first dose of study drug
Prior therapy for brain metastases is not required; patients may either have refused radiation therapy or have received prior radiation therapy; patients having received prior standard whole brain radiation therapy (WBRT) or stereotactic radiosurgery (SRS) must have completed treatment greater than  weeks prior to study initiation; patients are either inappropriate candidates for surgical resection or they may have refused surgical resection
Patients must be >/=  weeks beyond treatment with a cytotoxic chemotherapy regimen, or therapeutic radiation, or major surgery. Patients may have received palliative localized radiation immediately before or during treatment provided that radiation is not delivered to the only site of disease being treated under this protocol. For biologic/targeted agents patients must be >/=  half-lives or >/=  weeks form the last dose (whichever comes first).
Received radiation therapy within  weeks prior to Week , Day  of study treatment. Patients may not receive or have received any radiation therapy at the biopsy sites.
Patients who have previously received radiation therapy
Patients may not have received prior cytotoxic chemotherapy; however, nonplatinum/non-taxane chemotherapy used for radiation sensitization is allowed; patients may have received prior radiation therapy (including whole pelvic or vaginal brachytherapy), hormonal therapy, or therapy with biologic agents, but such therapy must be discontinued at least  weeks prior to entry on this study
Participant has received radiation therapy to the lung that is >  Gy within  months of the first dose of trial treatment
Patients who received other chemotherapeutics or investigational agents in addition to their radiation therapy and concomitant temozolomide treatment
Has received anticancer chemotherapy, surgical treatment, and/or radiation therapy (except palliative radiation therapy for disease-related pain with a consult with the sponsor's medical monitor) within ? weeks of first study treatment.
Subjects who have received extensive radiation therapy, including sternum, pelvis, scapulae, vertebrae or skull, within  weeks of the first day of study drug or received palliative low dose radiation therapy limited to limbs within  week of the first day of study drug, or subjects who have not recovered from side effects of such therapy.
Patients with locoregional disease that have not received appropriate standard locoregional therapy with surgery and/or radiation therapy
Patients must have received prior radiation therapy and standard temozolomide
Subject has received chemotherapy and/or radiation therapy (except palliative radiation therapy for disease-related pain) within ? weeks of first ADXS- infusion.
The patient has received chemotherapy, surgery, or radiotherapy (for therapeutic purposes) within  weeks of initiating study treatment ( weeks for bevacizumab or investigational drugs) or the patient has not recovered (grade >=  from side effects of the previous therapy); patients who receive palliative radiation therapy can be treated immediately after completion of radiation therapy
Patients currently receiving radiation therapy, or who have received radiation within  weeks from the start of therapy
Patients who have received radiation therapy, radionuclide therapy or undergone surgery within certain duration ( weeks) of enrollment
Participants must have received =<  months of prior chemotherapy for this disease without evidence of progressive disease with treatment; participants may have received prior radiotherapy provided approval has been obtained from the principal investigator (PI); participants with a history of radiation who have a platelet count < , due to radiation (disease, chemo, and other factors have been ruled out) will be excluded from this study
Patients who have received radiation therapy =<  weeks prior to study entry; patients who have received prior radiotherapy must have recovered from toxicity (=< grade ) induced by this treatment
Patients must be >=  weeks beyond treatment with a cytotoxic chemotherapy regimen, or therapeutic radiation, or major surgery; a confirmation (written or verbal) that there is no risk of surgical complications from a patients surgeon has to be obtained prior to starting therapy in patients with a history of major surgery within past  weeks; patients may have received palliative localized radiation immediately before or during treatment provided that radiation is not delivered to the only site of disease being treated under this protocol; for biologic/targeted agents patients must be >=  half-lives or >=  weeks form the last dose (whichever comes first)
Patients must have been treated with at least one prior treatment regimen that included carboplatin; patients who have received prior radiation therapy for this tumor are eligible
Patients who have received previous chemotherapy or radiation therapy to treat the current disease
Patients who have not recovered from the toxic effects of prior chemotherapy and/or radiation therapy will be excluded; guidelines for this recovery period are dependent upon the specific therapeutic agent being used:\r\n* Patients may not have received chemotherapy or bevacizumab =<  weeks (except for nitrosourea [ weeks] or metronomic dosed chemotherapy such as daily etoposide or cyclophosphamide [ week]) prior to starting the study drug unless patients have recovered from side effects of such therapy\r\n* Patients may not have received immunotherapy =<  weeks prior to starting the study drug unless patients have recovered from side effects of such therapy\r\n* Patients may not be less than  weeks from radiation therapy, unless progressive disease outside of the radiation field or  progressive scans at least  weeks apart or histopathologic confirmation\r\n* Patients must have completed all standard of care treatments, including surgical procedure, and radiation therapy (at least  Gy)\r\n** If the MGMT promoter in their tumor is known to be unmethylated, patients are not mandated to have received chemotherapy prior to participating in this trial\r\n** If the MGMT promoter in their tumor is known to be methylated or the MGMT promoter status is unknown at the time of screening, patients must have received at least one chemotherapy regimen prior to participating in this trial
Patients currently receiving radiation therapy or those having received radiation within  weeks of study entry
Patients who have received prior radiation or chemotherapy may be enrolled on this study
Patients who received investigational chemotherapy prior to radiation therapy are excluded from this study
Prior therapy: patients with prior history of mediastinal radiation exposure will be ineligible; patients may not have received prior chemotherapy, or antibody therapy for esophageal or GE-junction adenocarcinoma
Patients must be >=  weeks beyond treatment with a cytotoxic chemotherapy regimen, or therapeutic radiation, or major surgery; patients may have received palliative localized radiation immediately before or during treatment provided that radiation is not delivered to the only site of disease being treated under this protocol; for biologic/targeted agents patients must be >=  half-lives or >=  weeks form the last dose (whichever comes first)
Has received prior chemotherapy, targeted therapy, and radiation therapy within the past  months.
Patients should be at least four weeks from the last day of therapeutic radiation or cytotoxic chemotherapy or from antibody therapy, or at least five half-lives from non-cytotoxic targeted or biologic therapy; patients may have received palliative radiation immediately before (or during) treatment provided radiation is not to the only target lesion available
Patients who have received prior radiation therapy to the brain for any reason
Patients who have received other recent antitumor therapy including any standard chemotherapy or radiation within  days (and having passed the time of any actual or anticipated toxicities) prior to the first scheduled dose of the study treatment.
Received more than one course of radiation therapy or more than a total dose of  Gy. May have received radiosurgery as part of initial therapy; however, dose counts against total dose limit.
Received maximal radiation therapy
NON-PROGRESSED DIPG (STRATUM ): Patients must have received a minimum of  Gy focal irradiation administered over approximately  days prior to enrollment; patients must not have received any other prior therapy for treatment of their central nervous system (CNS) malignancy besides standard radiation therapy
Previous therapies: prior radiation therapies, immunotherapies, and investigational therapies are allowed as follows:\r\n* Radiation: prior radiation therapy is allowed with the following conditions:\r\n** Patients who have received minimal radiation therapy (=< % of their total marrow volume) must have completed it >=  weeks prior to the initiation of study treatment\r\n** Patients who have received radiation therapy that constituted > % but < % of their total marrow volume must have completed it >=  weeks prior to the initiation of study treatment\r\n** Patients who have received prior radiation to % or more of their total marrow volume will be excluded\r\n** Patients may be biopsied while undergoing radiation therapy as long as biopsy site is not in the radiation portal; however, they still have to wait the required amount of time from radiation to treatment even though the tumor board may have already occurred and a treatment plan assigned\r\n* Other therapies: prior investigational or targeted therapies and immunotherapies may be allowed following discussion with the principal investigator; if the principal investigator (PI) deems the prior treatment acceptable, patients must not have received these therapies for  days or five half-lives of the drug (whichever is lesser) prior to the initiation of study treatment and must have full recovery from any acute effects of these therapies; prior therapy with mitogen-activated protein kinase (MEK) inhibitors will not be allowed
If patients have received radiation therapy, there must be a one-month washout period
Patients having received radiation therapy in the month prior to enrollment
Patients must not have received radiation for a minimum of two weeks prior to study enrollment.
Patients going on Arm  must have received planned treatment with radiation therapy and concomitant temozolomide at least  days but no more than  days prior to starting treatment on this study; patients must have received at least % of planned temozolomide and radiation therapy with no grade  or grade  toxicity (except lymphopenia) attributed to the temozolomide; Arm  patients may not have received any other prior chemotherapy, immunotherapy or therapy with biologic agent (including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins, TIL, LAK or gene therapy), or hormonal therapy for their brain tumor; prior Gliadel wafers are allowed; glucocorticoid therapy is allowed
Patients who have previously received radiation therapy to areas of the lung or mediastinum near target(s)
Subjects who have previously received hyperthermia in conjunction with either radiation therapy or chemotherapy are eligible.
Patients who have received other recent antitumor therapy including any standard chemotherapy or radiation within  days and bevacizumab within  days (and having passed the time of any actual or anticipated toxicities) prior to the first scheduled dose of the study treatment
Patients with persistent or recurrent disease must have received definitive chemoradiation therapy as first line therapy; patients with advanced (stage IVB) disease may have received palliative radiation therapy
Have received surgery, chemotherapy, and/or radiation therapy
Patients may have received any of the following therapies: surgery, chemotherapy, hormones, biologics, or radiation
Subject has received radiation within the past  weeks
Diagnosis of breast cancer, received chemotherapy, and scheduled to receive  to  weeks of radiation therapy (radiation protocol of  Gy+)
Having received chemotherapy with or without radiation therapy
Patients must not have received prior regional therapy such as ablation, embolization, or radiation therapy for at least  weeks prior to the first dose of study treatment; patients who receive such therapy should have evidence of radiologic progression at this site or other progressing measurable disease
Have received radiation therapy or chemotherapy for any condition other than primary HNC
Patients should not have received chemotherapy or radiation therapy (localized radiation therapy is allowed to non-evaluable sites) between prior I-MIBG scan and F-MFBG administration
Patients must not have received prior chemotherapy or radiation for >=  weeks before study enrollment
Prior and current therapy:\r\n* For NF related benign tumor manifestations there is no standard effective medical treatment, and surgery is the only standard treatment; chemotherapy and radiation therapy are additional treatment options for malignant NF related tumors; for the purpose of this study subjects who have not previously received medical or surgical treatment, patients who have previously received medical or surgical treatment, and subjects who are currently receiving medical treatment and or radiation for a NF related manifestation will be eligible\r\n* Patients must be recovered from acute toxicities of prior therapy in order to be able to safely undergo biopsies proposed on the trial; prior and current treatment for NF related manifestations will be recorded on protocol -C-\r\n* Prior radiation therapy and chemotherapy in patients with MPNST must not have been administered within  weeks prior to enrollment
Patients who have received more than one previous therapy regimen (radiation or chemotherapy) are not eligible for this study
Must not have received prior radiation therapy or chemotherapy for this diagnosis
Patients may not have received prior chemotherapy or radiation therapy for lung cancer
Patients with no previous therapy other than biopsy or surgical resection of the primary tumor; patients can have received pre-operative radiation to the primary tumor site, but cannot have received radiation directly to, or in close approximation of, the lymph node basin
Subjects may have previously received pre-operative radiation therapy.
